Founded in 2014 and based in Rockville, MD, NeoImmuneTech (NIT) is a clinical-stage T cell-focused biotech company
dedicated to the discovery and development of novel immuno-therapeutics.
At NIT, we strive to expand the therapeutic horizon in Immuno-Oncology and Infectious Diseases
by greatly reducing the fatality and morbidity of life-threatening and debilitating diseases.
Led by our scientific founder, who invented our lead asset NT-I7 (efineptakin alfa), we are science driven and patient focused.
We believe that with NT-I7, the only clinical-stage long-acting human IL-7, we can enhance the body’s immune function
to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.
We have a profound belief, rooted in our science, that we have the power to transform patient care with unique assets
like NT-I7, and are committed to the pursuit of discovering their full potential in treating various diseases.
Founded in 2014 and based in Rockville, MD, NeoImmuneTech (NIT) is a clinical-stage T cell-focused biotech company
dedicated to the discovery and development of novel immuno-therapeutics.
At NIT, we strive to expand the therapeutic horizon in Immuno-Oncology and Infectious Diseases
by greatly reducing the fatality and morbidity of life-threatening and debilitating diseases.
Led by our scientific founder, who invented our lead asset NT-I7 (efineptakin alfa), we are science driven and patient focused.
We believe that with NT-I7, the only clinical-stage long-acting human IL-7, we can enhance the body’s immune function
to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.
We have a profound belief, rooted in our science, that we have the power to transform patient care with unique assets
like NT-I7, and are committed to the pursuit of discovering their full potential in treating various diseases.